Bioinformatics Biomax Has No Buzz, But Hey, It’s Still in Business | GenomeWeb

On a Thursday spring evening in Martinsried, Germany, Klaus Heumann is off to the biergarten after work. Unlike many of his bioinformatics industry peers, the 34-year-old CEO of Biomax seems to have few worries. Sure, the economy is generally unfavorable, he acknowledges, but his privately held software company, which experienced “dramatic” growth between 1998 and 2001, is still on an upward curve. “We’re not in a boom phase, but we still grew our revenue in 2002,” Heumann says.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.